Literature DB >> 15096409

Rubral lateropulsion due to vertebral artery dissection in a patient with Klippel-Feil syndrome.

Morvarid Karimi1, Mehrdad Razavi, Deema Fattal.   

Abstract

BACKGROUND: Neurologic deficits in patients with Klippel-Feil syndrome usually are attributed to direct compression of neuronal structures or hypoperfusion secondary to compression of the vertebral arteries by bony abnormalities.
OBJECTIVE: To describe a 38-year-old woman with known Klippel-Feil syndrome who developed lateropulsion.
RESULTS: The results of magnetic resonance imaging were consistent with rubrothalamic stroke. The cerebral angiogram confirmed vertebral artery dissection at the level of her previously observed bony abnormality.
CONCLUSIONS: Hypermobility adjacent to fused vertebrae subjects the vertebral artery to increased shear forces. Thus, Klippel-Feil syndrome may be a predisposing factor for vertebral artery dissection. Moreover, to our knowledge, this case represents the second known case of rubral lateropulsion.

Entities:  

Mesh:

Year:  2004        PMID: 15096409     DOI: 10.1001/archneur.61.4.583

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  3 in total

1.  Isolated axial lateropulsion caused by an acute lateral medullary infarction involving the dorsal spinocerebellar tract: A case report.

Authors:  Marco Sparaco; Maria Carmela Addonizio; Giancarlo Apice; Giuseppina Cafasso; Amedeo D'Alessio; Gabriella Di Iasi; Carmine Franco Muccio
Journal:  Brain Circ       Date:  2022-09-21

2.  Profiles of Vertebral Artery Dissection with Congenital Craniovertebral Junction Malformation: Four New Cases and a Literature Review.

Authors:  Sufang Xue; Yi Yang; Pengyu Li; Ping Liu; Xiangying Du; Xin Ma
Journal:  Neuropsychiatr Dis Treat       Date:  2020-10-22       Impact factor: 2.570

3.  Truncal contrapulsion in pretectal syndrome.

Authors:  Jae-Hyeok Heo; Ji Soo Kim; Kyung-Bok Lee; Keun-Hwa Jung; Hyun-Kyung Kim; Sung-Hun Kim; Jae-Kyu Roh
Journal:  J Clin Neurol       Date:  2006-03-20       Impact factor: 3.077

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.